Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
1. Introduction Medical cannabis and its extracted cannabinoids are used for the treatment of chronic pain, spasticity, epilepsy and anxiety in humans, and have been gaining popularity for similar indications in veterinary medicine in recent years (1–5). The cannabinoids most commonly known are cannabidiol (CBD), cannabidiolic acid (CBDA) and ∆9-tetrahydrocannabinol (THC) (6).
ORIGINAL ARTICLE The abstract is available in Portuguese in the Supporting Information section of the online version of this article Summary Background Topical dexamethasone and prednisolone are currently the mainstay treatment for equine ophthalmic inflammatory diseases, such as equine recurrent uveitis. Comparative pharmacokinetic studies in horses are lacking and current guidelines are mainly based on empirical data and extrapolation from other species.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.